Medical News

RSS

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides, Inc. reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study.

21 Mar 2011

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

21 Mar 2011

Advanced Cell Technology reduces 2010 debt to less than $1 million

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today 2010 year-end results for the period ended December 31, 2010. The Company utilized $8.8 million in cash for operations during the year, compared to $5.1 million in the year-earlier period.

21 Mar 2011

Medicago launches clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States. The primary safety and immunogenicity results for this trial are expected within three months.

21 Mar 2011

Life Technologies enters clinical trials for DNA SBT platform for analysis of Human Leukocyte Antigen system

Life Technologies Corporation today announced that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human Leukocyte Antigen (HLA) system. Submission for 510(k) clearance of this SBT platform will follow completion of the clinical trials, which is anticipated this summer.

21 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline is consistent with review as a Class II resubmission.

21 Mar 2011

NDS Surgical Imaging launches dynamic color calibration solution for surgical displays

NDS Surgical Imaging (NDSsi) today launched its proprietary Color Correction Technology (CCT). This dynamic color calibration solution is designed to fine tune the color response of surgical displays, uniquely correcting high-definition images in real-time on a pixel-by-pixel basis. The result is accurate, consistent color across all displays, conforming to international standards.

21 Mar 2011

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher T. Nguyen will hold an oral presentation on a study titled "Mandibular Changes Produced by Skeletal Anchorage Assisted Orthopedic Traction."

21 Mar 2011

Assisted Living Federation of America names winners of 2011 ALFA Best of the Best Awards

The Assisted Living Federation of America (ALFA) today announced the winners of this year's ALFA Best of the Best Awards. These annual awards honor programs demonstrating innovation in the field of senior living and embracing the principles of choice, independence, dignity and quality of life for seniors. ALFA will recognize the winning programs at the ALFA 2011 Conference & Expo, April 5-7 in Orlando, Florida.

21 Mar 2011

NDS Surgical Imaging introduces new 26" Radiance G2 High-Bright displays with stabilized LED backlight

NDS Surgical Imaging (NDSsi) today announced the industry's first stabilized LED backlight, available in all new 26" Radiance G2 High-Bright surgical displays. Backlight stabilization assures consistent brightness of images over the life of the display—specified at 25,000 hours—without any dimming or compromise in luminance output. The result is a new level of image clarity and consistency, with enhanced brightness, contrast and color.

21 Mar 2011

Physical ill-health reduces life expectancy of people with severe mental illness

Physical ill-health is rife among the severely mentally ill in Britain, according to new research published today by the University of East Anglia (UEA).

21 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

21 Mar 2011

Elevations in 5 amino acids may signal future disease risk

Measuring the levels of small molecules in the blood may be able to identify individuals at elevated risk of developing type 2 diabetes as much as a decade before symptoms of the disorder appear.

21 Mar 2011

More opportunities to develop therapies for protein misfolding

Romping clumps of misfolded proteins are prime suspects in many neurological disorders including Alzheimer's, Parkinson's, and Creutzfeld-Jakob Disease. Those diseases are devastating and incurable, but a team of biologists at Brown University reports that cells can fix the problems themselves with only a little bit of help. The insight suggests that there are more opportunities to develop a therapy for protein misfolding than scientists had thought.

21 Mar 2011

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Chronic fatigue syndrome (CFS) is characterized by unexplained and debilitating tiredness and is associated with headaches, disrupted sleep, muscle pain and difficulty in concentrating. New research published by BioMed Central's open access journal BMC Medicine shows that ethnicity, depression, lack of exercise or social support, and social difficulties are major risk factors for CFS.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Almac, Exco InTouch enter exclusive integrated patient management alliance

The Almac Group and Exco InTouch announced today that Almac's Clinical Technologies business unit, the leading provider of IXRS(R) (Interactive Voice and Web Response) services relating to patient and drug supply management, has formed an exclusive integrated patient management alliance with Exco InTouch, an innovative firm specializing in patient recruitment, retention, compliance and ePRO services.

21 Mar 2011

Study on biodegradable tooth-binding micelles that inhibit Streptococcus mutans biofilm growth

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher F. Cheni will hold an oral presentation on a research study titled "Biodegradable Tooth-binding Micelles Inhibit Streptococcus mutans (S. mutans) Biofilm Growth."

21 Mar 2011

Medical News

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

Advanced Cell Technology reduces 2010 debt to less than $1 million

Medicago launches clinical development of seasonal flu vaccine

Life Technologies enters clinical trials for DNA SBT platform for analysis of Human Leukocyte Antigen system

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

NDS Surgical Imaging launches dynamic color calibration solution for surgical displays

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Assisted Living Federation of America names winners of 2011 ALFA Best of the Best Awards

NDS Surgical Imaging introduces new 26" Radiance G2 High-Bright displays with stabilized LED backlight

Physical ill-health reduces life expectancy of people with severe mental illness

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

Elevations in 5 amino acids may signal future disease risk

More opportunities to develop therapies for protein misfolding

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Almac, Exco InTouch enter exclusive integrated patient management alliance

Study on biodegradable tooth-binding micelles that inhibit Streptococcus mutans biofilm growth

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

Latest News